Protocol Ledger

NCT05696717 · Phase III · ACTIVE NOT RECRUITING

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Interventional Phase III clinical trial protocol NCT05696717 sponsored by Theravance Biopharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-27 Enrollment: 102 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05696717
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)102 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05696717
Protocol FieldVerified Registry Value
NCT IdentifierNCT05696717
Consolidated Lead SponsorTheravance Biopharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment102 participants (ESTIMATED)
Registered Start Date2023-06-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI